Boston Scientific says a cyberattack is likely to affect its business and may reduce sales and profit in 2026. The company also indicates that it is unlikely to meet its previously issued 2026 sales and profit forecast range.
The outlets report the company’s assessment of financial impact following the attack, while describing it as a factor that contributes to weaker-than-expected outlook for the later-year period. The coverage focuses on what the cyber incident means for forward guidance, including whether performance targets remain achievable.
Across the reports, the core emphasis is the same: the cyberattack is presented as a material driver of the company’s updated expectations for 2026. However, each outlet frames the update slightly differently—some highlight the likely impact on 2026 sales and profit, while others stress the likelihood that the forecast will not be met. The reports also reflect that the company is communicating revised expectations rather than detailing immediate, quarter-by-quarter results in depth.
